Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2 /4 :: CREM fusions
The Journal of Pathology · 2024
DOI: 10.1002/path.6350 ↗At a glance
Journal article in The Journal of Pathology, 2024. Written by Joanna Cyrta and 14 co-authors. Institution: Department of Pathology, Institut Curie, PSL Research University, Paris, France. Major MEDLINE topics: Transcription Factors, Cyclic AMP Response Element Modulator, DNA Helicases, Nuclear Proteins. Cited 7 times so far (Crossref); 41 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, Kristin Ann Carr Foundation, Cycle for Survival.
Abstract (original language)
CREB gene family ( ATF1 , CREB1 , CREM ) fusions with either EWSR1 or FUS gene partners drive the pathogenesis of a wide range of neoplasms, including various soft tissue tumors, intracranial myxoid mesenchymal tumors (IMMTs), hyalinizing clear cell carcinoma (HCCC), and rare mesotheliomas. Recently, a SMARCA2 :: CREM fusion was reported in one case each of IMMT and HCCC. In this study, we expand the clinicopathologic and molecular spectrum of these neoplasms by describing three additional cases with SMARCA2 :: CREM and one with a novel SMARCA4 :: CREM fusion, highlighting the recurrent potential of additional CREB gene fusion partners beyond FET family members. To evaluate if these fusions define a new pathologic entity, we performed a comprehensive genomic and methylation analysis and compared the results to other related tumors. Tumors occurred in children and young adults (median age 20 years) and spanned a broad anatomic distribution, including soft tissue, intracranial, head and neck, and prostatic urethra. Microscopically, the tumors shared an undifferentiated round to epithelioid cell phenotype and a hyalinized fibrous stroma. Immunohistochemically, a polyphenotypic profile was observed, with variable expression of SOX10, desmin, and/or epithelial markers. No targetable genomic alterations were found using panel‐based DNA sequencing. By DNA methylation and transcriptomic analyses, tumors grouped closely to FET :: CREB entities, but not with SMARCA4 / SMARCB1 ‐deficient tumors. High expression of CREM by immunohistochemistry was also documented in these tumors. Patients experienced local recurrence ( n = 2), locoregional lymph node metastases ( n = 2), and an isolated visceral metastasis ( n = 1). Overall, our study suggests that SMARCA2/4 :: CREM fusions define a distinct group of neoplasms with round cell to epithelioid histology, a variable immunoprofile, and a definite risk of malignancy. Larger studies are needed to further explore the pathogenetic relationship with the FET :: CREB family of tumors. © 2024 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, Institut Curie, PSL Research University, Paris, France.
- Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Department of Neuropathology, GHU Paris Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
- Department of Pathology, University of Utah/ARUP Laboratories, Salt Lake City, UT, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Pathology, Advent Health, Orlando, FL, USA.
ORCID profiles: Joanna Cyrta, Josephine K Dermawan, Arnault Tauziède-Espariat, Franck Bourdeaut
Funding
- NCI NIH HHS
- Kristin Ann Carr Foundation
- Cycle for Survival
Cite
APA
Cyrta, J., Dermawan, J. K., Tauziède-Espariat, A., Liu, T., Rosenblum, M., Shroff, S., Katabi, N., Cardoen, L., Guillemot, D., Masliah-Planchon, J., Hoare, O., Delattre, O., Bale, T., Bourdeaut, F., & Antonescu, C. R. (2024). Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2 /4 :: CREM fusions. The Journal of Pathology. https://doi.org/10.1002/path.6350
Vancouver
Cyrta J, Dermawan JK, Tauziède-Espariat A, Liu T, Rosenblum M, Shroff S, et al. Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2 /4 :: CREM fusions. The Journal of Pathology. 2024. doi:10.1002/path.6350
BibTeX
@article{Cyrta2024,
author = {Cyrta, Joanna and Dermawan, Josephine K and Tauziède-Espariat, Arnault and Liu, Ting and Rosenblum, Marc and Shroff, Seema and Katabi, Nora and Cardoen, Liesbeth and Guillemot, Delphine and Masliah-Planchon, Julien and Hoare, Owen and Delattre, Olivier and Bale, Tejus and Bourdeaut, Franck and Antonescu, Cristina R},
title = {Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2 /4 :: CREM fusions},
journal = {The Journal of Pathology},
year = {2024},
doi = {10.1002/path.6350}
}
EUVIMED